"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment

CONCLUSIONS: Patients identified cost, restrictive pharmacy benefits, and initial side effects as barriers to PARP-I usage. Having insurance and a supportive care team were identified as facilitators. Enhancing communication about PARP-I cost and side effects could improve patient experience and receipt of evidence-based maintenance therapy in ovarian cancer.PMID:38691987 | DOI:10.1016/j.ygyno.2024.04.018

Source: Gynecologic Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Anna Jo Bodurtha Smith Caroline O'Brien Ashley Haggerty Emily M Ko Katharine A Rendle Source Type: research